Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2020 / Cilt: 54 - Sayı: 2

Sleep Quality in Psoriasis Patients and its Relations with Possible Affecting Factors

Pages
181–187
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Controlsof disease activation and prevention of progression in DM may provide to keep SQ in PS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Psoriasis (PS) is a chronic, immune-mediated inflammatory skin disease.
📊
Key Findings & Data:PS may lead to significant effects on healthrelatedquality of life (HRQoL) and other outcomes.
💡
Conclusion & Impact:Controlsof disease activation and prevention of progression in DM may provide to keep SQ in PS.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: Psoriasis (PS) is a chronic, immune-mediated inflammatory skin disease. PS may lead to significant effects on healthrelatedquality of life (HRQoL) and other outcomes. In the present study, an investigation into sleep quality (SQ), and its possiblerelations with factors which may affect SQ were aimed.Methods: A total of 74 subjects from both sexes were enrolled in this study, between January and July 2017. Patients were evaluatedwith their demographics, body mass index (BMI), Psoriasis Area Severity Index (PASI), Pittsburgh Sleep Quality Index (PSQI),Psoriasis Quality of Life Index (PQLI), Self Perception Scale (SPS). Additionally, accompanying chronic diseases, disease duration andseverity of pruritus were recorded. Obtained PSQI values were compared with the mentioned parameters concerning the significanceof their relations with it. SPSS version 24, 2016 was used to analyse the data, and significance was evaluated with p-values of 0.8.Results: Thirty-seven female and 37 male were studied. The mean age of total of the study population was 47.21±13.91. Mean BMIand mean duration were 30.09± 4.68 kg/m2, and 10.58±9.1 months. Mean values of PASI, PSQI, SPS, and PQLI of the study groupwere 19.79±16.99, 9.14±5.09, 142.12±23.83, and 21.94±16.31, respectively. Approximately thirty-one percent of them had at leastone chronic disease. Alcohol and smoking rates were 17.56%, 50%. PASI was positive/strongly correlated with PQLI and negative/weakly correlated with SPS. No correlation was detected between PSQI values and age, gender, BMI, and SPS values. PSQI wasmoderately correlated with PQLI, diabetes mellitus (DM), and pruritus severity, whereas it was weak correlated with PASI, hypertension(HT), thyroid diseases and disease duration. PASI and DM showed a predictive effect on SQ.Conclusion: SQ is affected by certain factors, such as QoL, disease severity, disease duration, pruritus severity, accompanying disorders,such as HT, DM and thyroid diseases, in which disease severity and DM have predictive effects on SQ in PS patients. Controlsof disease activation and prevention of progression in DM may provide to keep SQ in PS.

🔖

Cite This Article

TAŞ, F. B., KABELOĞLU, V., SOYSAL, A., ATAKLI, D. (2020). Sleep Quality in Psoriasis Patients and its Relations with Possible Affecting Factors. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 54 - Sayı: 2, 181–187. https://ajindex.com/articles/358565

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Gülekon A. Psoriasis ve benzeri dermatozlar. In: Tüzün Y, Gürer MA, Serdaroğlu S, Oğuz O, Aksungur VL, editors. 3rd ed. Dermatoloji. Istanbul: Nobel Kitabevi; 2008. p. 745–64
  2. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64 Suppl 2:ii18–ii25
  3. Machado-Pinto J, Diniz Mdos S, Bavoso NC. Psoriasis: new comorbidities. An Bras Dermatol 2016;91:8–14
  4. Berhanu H, Mossie A, Tadesse S, Geleta D. Prevalence and Associated Factors of Sleep Quality among Adults in Jimma Town, Southwest Ethiopia: A Community-Based Cross-Sectional Study. Sleep Disord 2018;2018:8342328
  5. Ranjbaran Z, Keefer L, Stepanski E, Farhadi A, Keshavarzian A. The relevance of sleep abnormalities to chronic inflammatory conditions. Inflamm Res 2007;56:51–7
  6. Shutty BG, West C, Huang KE, Landis E, Dabade T, Browder B, et al. Sleep disturbances in psoriasis. Dermatol Online J 2013;19:1 7. Gowda S, Goldblum OM, McCall WV, Feldman SR. Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol 2010;63:114–23
  7. Buslau M, Benotmane K. Cardiovascular complications of psoriasis: does obstructive sleep apnoea play a role?. Acta Derm Venereol 1999;79:234
  8. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63
  9. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii65–ii73
  10. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213
  11. Agargun MY, Kara H, Anlar O. The validity and reliability of the Pittsburgh Sleep Quality Index. Turk Psikiyatri Derg 1996;7:107–15
  12. İnanır I, Aydemir Ö, Gündüz K, Danacı AE, Ermertcan AT. Developing a quality of life questionnaire in patients with psoriasis. Turkderm 2003;37:189–95
  13. Hovardaoğlu S. Vücut Algısı Ölçeği. Psikiyatri, Psikoloji, Psikofarmakoloji Dergisi (3P). Testler Özel Eki 1992;1:26–7
  14. Wohlrab J, Fiedler G, Gerdes S, Nast A, Philipp S, Radtke MA, et al. Recommendations for detection of individual risk for comorbidities in patients with psoriasis. Arch Dermatol Res 2013;305:91–8
  15. Jensen P, Zachariae C, Skov L, Zachariae R. Sleep disturbance in psoriasis: a case-controlled study. Br J Dermatol 2018;179:1376– 84
  16. Biçici F, Hayta SB, Akyol M, Özçelik S,